Blueshift Asset Management, LLC Myovant Sciences Ltd. Transaction History

Blueshift Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.78 - $14.69 $90,092 - $170,110	-11,580 Reduced 52.69%	10,396 $129,000
Q1 2022 May 12, 2022	BUY	$11.38 - $16.4 $250,086 - $360,406	21,976 New	21,976 $293,000
Q4 2021 Feb 11, 2022	SELL	$14.31 - $23.87 $1.82 Million - $3.03 Million	-126,915 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$18.94 - $26.99 $779,854 - $1.11 Million	-41,175 Reduced 24.5%	126,915 $2.85 Million
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $2.87 Million - $4.13 Million	168,090 New	168,090 $3.83 Million
Q3 2020 Nov 13, 2020	SELL	$14.05 - $22.6 $144,953 - $233,164	-10,317 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$7.34 - $20.84 $75,726 - $215,006	10,317 New	10,317 $213,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.